

## What You Need to Know about PrEP

### References

- Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. *Lancet Infect Dis*. 2014;14(11):1055-1064.
- Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med*. 2012;367(5):399-410.
- Center for Disease Control. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2014: A clinical practice guideline. 2014; <https://www.cdc.gov/hiv/pdf/prepguidelines2014.pdf>.
- Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. *The Lancet*. 2013;381(9883):2083-2090.
- Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med*. 2016;375(9):830-839.
- Deutsch MB, Glidden DV, Sevelius J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. *The Lancet HIV*. 2015;2(12):e512-e519.
- Food and Drug Administration. Truvada Label. 2012; [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2012/021752s030lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021752s030lbl.pdf).
- Garrett KL, Cottrell ML, Prince HM, et al. Concentrations of TFV and TFVdp in female mucosal tissues after a single dose of TAF. 3rd Conference on Retroviruses and Opportunistic Infections; February 22-25, 2016; Boston.
- Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363(27):2587-2599.
- HIV/AIDS Hepatitis STD and TB Administration (HAHSTA). HAHSTA Annual Report 2014. 2014; [www.doh.dc.gov/hahsta](http://www.doh.dc.gov/hahsta).
- Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2015;372(6):509-518.
- McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. *Lancet*. 2016;387(10013):53-60.

- Molina JM, Capitant C, Spire B, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. *N Engl J Med*. 2015;373(23):2237-2246.
- Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. *JAMA*. 2014;312(4):362-371.
- Mugwanya K, Baeten J, Celum C, et al. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. *J Infect Dis*. 2016;214(7):1050-1057.
- Mugwanya KK, Wyatt C, Celum C, et al. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis. *J Acquir Immune Defic Syndr*. 2016;71(4):374-380.
- Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women- a phase 2, double-blind, randomized, placebo-controlled trial. *PLoS Clin Trials*. 2007;2(5):e27.
- Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. *The Lancet*. 2015;385(9987):2606-2615.
- Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. *AIDS*. 2012;26(7):867-875.
- Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. *J Acquir Immune Defic Syndr*. 2015;68(3):337-344.
- Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. *N Engl J Med*. 2012;367(5):423-434.
- Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. *N Engl J Med*. 2012;367(5):411-422.
- Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. *Cochrane Database Syst Rev*. 2002(1):CD003255.